Abstract
Inflammatory bowel disease is thought to result from inappropriate activation of mucosal immune responses. Intestinal epithelial cells produce interleukin (IL)-7 that serves as a regulatory factor for IL-7 receptor (IL-7R)+ mucosal lymphocytes. The pivotal role of mucosal IL-7 / IL-7R dependent signals in the activation of mucosal immune responses that lead to the development of chronic intestinal inflammation are demonstrated. Therapeutic approaches targeting IL-7 / IL-7R signal pathway may be feasible in the treatment of inflammatory bowel disease.
Keywords: il-7, il-7 receptor, t cells, mucosal immunity, ibd
Current Drug Targets - Inflammation & Allergy
Title: Therapeutic Approaches to Chronic Intestinal Inflammation by Specific Targeting of Mucosal IL-7 / IL-7R Signal Pathway
Volume: 2 Issue: 2
Author(s): Mamoru Watanabe, Motomi Yamazaki, Ryuichi Okamoto, Shinya Ohoka, Akihiro Araki, Tetsuya Nakamura and Takanori Kanai
Affiliation:
Keywords: il-7, il-7 receptor, t cells, mucosal immunity, ibd
Abstract: Inflammatory bowel disease is thought to result from inappropriate activation of mucosal immune responses. Intestinal epithelial cells produce interleukin (IL)-7 that serves as a regulatory factor for IL-7 receptor (IL-7R)+ mucosal lymphocytes. The pivotal role of mucosal IL-7 / IL-7R dependent signals in the activation of mucosal immune responses that lead to the development of chronic intestinal inflammation are demonstrated. Therapeutic approaches targeting IL-7 / IL-7R signal pathway may be feasible in the treatment of inflammatory bowel disease.
Export Options
About this article
Cite this article as:
Watanabe Mamoru, Yamazaki Motomi, Okamoto Ryuichi, Ohoka Shinya, Araki Akihiro, Nakamura Tetsuya and Kanai Takanori, Therapeutic Approaches to Chronic Intestinal Inflammation by Specific Targeting of Mucosal IL-7 / IL-7R Signal Pathway, Current Drug Targets - Inflammation & Allergy 2003; 2 (2) . https://dx.doi.org/10.2174/1568010033484269
DOI https://dx.doi.org/10.2174/1568010033484269 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Cytidine Deaminases as a Weapon Against Retroviruses and a New Target for Antiviral Therapy
Mini-Reviews in Medicinal Chemistry Comparative Pharmacokinetics, Tissue Distribution, Excretion of Recombinant Liver-Targeting Interferon with IFN α2b Administered Intramuscular in Rats
Current Pharmaceutical Biotechnology Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design Doping Metal into Calcium Phosphate Phase for Better Performance of Bone Implant Materials
Recent Patents on Materials Science MicroRNA Gene Networks in Oncogenesis
Current Genomics Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients
Inflammation & Allergy - Drug Targets (Discontinued) Yeast Genomics and Drug Target Identification
Combinatorial Chemistry & High Throughput Screening Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry The Pollen Enigma: Modulation of the Allergic Immune Response by Non-Allergenic, Pollen-Derived Compounds
Current Pharmaceutical Design PET Imaging for Gene & Cell Therapy
Current Gene Therapy Synergistic Activation of Leukocytes by Bacterial Chemoattractants: Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Inhibition of RNA Virus Infections with Peptide-Conjugated Morpholino Oligomers
Current Pharmaceutical Design Editorial [Hot Topic: Ion Channels as Therapeutic Targets for Neuropathic Pain (Executive Editor: Char-Chang Shieh)]
Current Pharmaceutical Design Oral Administration of Sustained Release Niacin Inhibits Platelet Aggregation
Current Clinical Pharmacology Preface
Current Pharmaceutical Design Clopidogrel Resistance: Implications for Coronary Stenting
Current Pharmaceutical Design Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors
Current Drug Targets